Public health officials seem to not realize the potential role of COVID-19 vaccines in accelerating the development of secretly adapted coronaviruses. In fact, they still haven’t acknowledged the existence of widespread human infection with secretly adapted monkey-derived viruses. These viruses were unintentionally introduced into humans through the polio vaccine. This resulted from the use of polio vaccines grown in cultured kidney cells of cytomegalovirus-infected monkeys.
A misconception is that current COVID-19 vaccines provide immunity that is at par with natural infections. This is clearly not the case. First, the vaccine is given by intramuscular injection, while natural infection occurs through the respiratory mucosa. Intramuscular injections are not particularly effective in stimulating the growth of mucosal immunoglobulin A (IgA) antibodies or resident cytotoxic T lymphocytes (CTLs). The low level of vaccine-induced mucosal immunity means that upon exposure to the SARS-CoV-2 virus, a proportion of vaccinated individuals will likely have a permanent, subclinical infection that is confined to the superficial respiratory mucosa . Public health officials pointed to the possibility, insisting that those who are immunized would continue to wear masks. However, low levels of persistent infection will provide opportunities for the emergence of forms of the virus. Some of these will be more contagious, while others will be able to better avoid vaccine-developed immunity and, therefore, become more widespread throughout the body.
The other major difference between vaccine and natural infection is the FDA’s permission to use a single virus component in a vaccine, namely the spike protein. It is far easier for natural infections to cause virus modification, or even removal, of a component than to have concurrent changes in multiple antigens targeted by immunity. Removing the spike protein is possible because coronaviruses have other means of entering cells. The virus can then more easily mutate the remaining genes that code for relatively few virus components that are normally targeted by cellular immunity.
The persistence of subclinical infection due to the relative lack of mucosal immunity elicited by intramuscular injection and the systemic immune response being restricted to spike proteins only, may occur more rapidly than natural infection, forming stealthy adapted coronaviruses. For. One consequence of this premise is that the English, South African and Brazilian versions probably originated in individual participants of the COVID-19 vaccine trials conducted in each country. With widespread vaccine use, many more variants are to be expected, including stealth adapted coronaviruses.
There’s another very related feature in the stealth customization. It is the incorporation of additional genetic sequences that are probably necessary for the virus to regain infectivity. The added sequences can come from cellular genomes and the genomes of other microbes. For example, this has allowed polio vaccine-derived stealth adapted viruses to bring cellular sequences from monkeys to humans.
The brain is particularly susceptible to symptomatic diseases caused by cryptically adapted viruses. These viruses can also be cultured from patients with chronic fatigue syndrome (CFS) and children with autism. Long covid syndrome has many clinical features in common with CFS. Unless proven otherwise, Long COVID syndrome should be treated as a viral disease with the potential for human-to-human transmission during pregnancy. It is important to start cultivating blood samples from patients with long covid syndrome and to sequence any resulting virus.
Although the cellular immune system will not normally engage with secretly adapted viruses, they can be suppressed through the alternative cellular energy (ACE) pathway. This pathway is likely to occur before all life forms obtain energy from photosynthesis and food metabolism in plants. In humans and animals, the brain is probably the major receiver of life-force energy for the ACE pathway. The attracted energy is then transferred to the body fluids where it is expressed as an extra-kinetic activity. The energy is called KELEA, an abbreviation for kinetic energy limited electrostatic attraction. KELEA can also be added to water, later called KELEA sublime water. Wearable pouches containing this water and inhaling nebulized mist with water are being evaluated as simple means of augmenting the ACE pathway. These approaches can suppress both conventional and stealthily adapted virus diseases.
A more detailed discussion on these topics can be found in the book “Stealth Adapted Viruses; Alternative Cellular Energy (ACE) and KELEA Activated Water”. Supporting information is also available on the following sites: